Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VIPR2 | P41587 | 15/20 | 0.43 |
| ▸ | MMP9 | P14780 | 3/20 | 0.41 |
| ▸ | MMP1 | P03956 | 2/20 | 0.39 |
| ▸ | MMP2 | P08253 | 2/20 | 0.39 |
| ▸ | MMP8 | P22894 | 2/20 | 0.39 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.39 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.39 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.39 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.39 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.39 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5220607 | 1.00 | VIPR2 (0.43) | VIPR2MMP9MMP1MMP2MMP8 | |
| SCHEMBL5220613 | 1.00 | VIPR2 (0.43) | VIPR2MMP9MMP1MMP2MMP8 | |
| SCHEMBL5225206 | 1.00 | VIPR2 (0.43) | VIPR2MMP9MMP1MMP2MMP8 | |
| SCHEMBL5381508 | 0.91 | VIPR2 (0.41) | VIPR2MMP9MMP1PSEN1PSEN2 | |
| SCHEMBL5381516 | 0.91 | VIPR2 (0.41) | VIPR2MMP9MMP1PSEN1PSEN2 | |
| SCHEMBL5218168 | 0.81 | CTSD (0.44) | MMP9MMP1MMP2MMP8 | |
| SCHEMBL5218164 | 0.81 | CTSD (0.44) | MMP9MMP1MMP2MMP8 | |
| SCHEMBL6102453 | 0.78 | VIPR2 (0.40) | VIPR2MMP9MMP1MMP2MMP8 | |
| SCHEMBL5433804 | 0.78 | VIPR2 (0.40) | VIPR2MMP9MMP1MMP2MMP8 | |
| SCHEMBL5394031 | 0.78 | KLK5 (0.51) | VIPR2PSEN1PSEN2APH1BNCSTN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1567488-B1 | HYDROXYETHYLAMINE DERIVATIVES FOR THE TREATMENT OF ALZHEIMER'S DISEASE | GLAXO GROUP LTD (GB) | 2007-02-21 | — | — | EP | disclosed |